Henderson Jeffrey William — SEC Form 4 filings
SEC reporting owner CIK 1324015. 18 Form 4 filings on record with FilingPulse; latest filed 2026-05-07.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-01-25 to 2026-05-07. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,500 shares, $350,430 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 8 legs across 5 filings — 25,000 shares, $1,378,719 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
- Largest priced transaction: sale of 10,000 shares @ $50.01 ($500,060) in HALOZYME THERAPEUTICS, INC., filed 2025-01-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. (HALO) | Director | 8 | — | 8 legs · 25,000 sh · $1,378,719 | 6 |
| BECTON DICKINSON & CO (BDX) | Director | 4 | 1 leg · 1,500 sh · $350,430 | — | 3 |
| QUALCOMM INC/DE (QCOM) | Director | 6 | — | — | 10 |
Form 4 filings — Henderson Jeffrey William
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-07 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 3,796 @ $0 · Grant/award (A): 6,040 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | QUALCOMM INC/DE (QCOM) | Grant/award (A): 2,563 @ $0 | EDGAR |
| 2026-03-09 | 4 | QUALCOMM INC/DE (QCOM) | Option exercise (M): 2,355 @ $0 · Disposition to issuer (D): 759 @ $135.69 · Option exercise (M): 2,355.20 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | BECTON DICKINSON & CO (BDX) | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2025-05-02 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 4,165 @ $0 · Grant/award (A): 5,750 (derivative) @ $0 | EDGAR |
| 2025-04-28 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 4,297 @ $60.34 · Sale (S): 200 @ $60.99 | EDGAR |
| 2025-04-01 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 503 @ $64.05 | EDGAR |
| 2025-03-20 | 4 | QUALCOMM INC/DE (QCOM) | Grant/award (A): 2,097 @ $0 | EDGAR |
| 2025-03-10 | 4 | QUALCOMM INC/DE (QCOM) | Option exercise (M): 1,901 @ $0 · Option exercise (M): 1,901.04 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 1,795 @ $57.93 · Sale (S): 3,205 @ $59.12 | EDGAR |
| 2025-02-10 | 4 | BECTON DICKINSON & CO (BDX) | Purchase (P): 1,500 @ $233.62 | EDGAR |
| 2025-02-04 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 1,100 @ $55.94 · Sale (S): 3,900 @ $56.41 | EDGAR |
| 2025-01-30 | 4 | BECTON DICKINSON & CO (BDX) | Grant/award (A): 930 @ $0 | EDGAR |
| 2025-01-07 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 10,000 @ $50.01 | EDGAR |
| 2024-04-29 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 6,501 @ $0 · Grant/award (A): 8,804 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | QUALCOMM INC/DE (QCOM) | Option exercise (M): 2,056 @ $0 · Option exercise (M): 2,056.64 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | QUALCOMM INC/DE (QCOM) | Grant/award (A): 1,624 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | BECTON DICKINSON & CO (BDX) | Grant/award (A): 900 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1324015 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →